BSE filing, NSE: AUROPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Aurobindo Pharma Ltd: key numbers
- Share price
- ₹1,644.80
- Market cap
- ₹95,530 Cr
- Revenue (annual)
- ₹33,653 Cr
- Net profit (annual)
- ₹3,505 Cr
- P/E (TTM)
- 24.2×Sector 46.1×
- Promoter holding
- 51.88%+0.00% QoQ
- FII holding
- 17.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aurobindo Pharma Ltd
All →Aurobindo Pharma Board Meeting Date
Aurobindo Pharma's board meets 4 November 2026 to consider Q2 and half-year results and a possible interim dividend. Trading window stays closed until 6 November.
Aurobindo Pharma Other Announcement
Aurobindo Pharma Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as mandated by SEBI regulations.
Aurobindo Pharma Business Update
Aurobindo Pharma received USFDA final approval for Perampanel Tablets in multiple strengths. The product will be manufactured by its subsidiary and launched in Q3FY27.
Aurobindo Pharma Acquisition
Aurobindo Pharma's subsidiary, Apitoria Pharma, has completed the acquisition of the Contract Research Services business of A1 Biochem Group. The deal integrates CRO capabilities into Apitoria's operations.
Aurobindo Pharma Acquisition Worth ₹146.4 Cr
Aurobindo Pharma's subsidiary acquired 100% ownership of US-based A1 Biochem Labs LLC for USD 15.247 million in an all-cash deal.
- Value
- ₹146.4 Cr
Aurobindo Pharma Merger & Restructuring Worth ₹33.8 Cr
Aurobindo Pharma's subsidiary, Apitoria Pharma, completed a 20% stake dilution in A1 Biochem Labs. Dr. Rajendra Gadikota subscribed to securities worth ₹33.80 Crore.
- Value
- ₹33.80 Cr
Other board meeting date announcements
All →Tatia Global Vennture Board Meeting Date
Tatia Global Vennture will hold a board meeting on 05 Nov 2026 to consider unaudited standalone and consolidated half-yearly results for September 2026. Trading window closes 01 Oct to 07 Nov 2026.
Landmarc Leisure Corporation Board Meeting Date
Landmarc Leisure scheduled a board meeting for 06 Nov 2026 to approve Q2 FY27 results. Trading window closes from 01 Oct to 08 Nov 2026.
Augmont Enterprises Board Meeting Date
Augmont Enterprises scheduled a Board meeting for November 4, 2026, to approve unaudited Q1 and H1 financial results. Trading window remains closed until 48 hours post-declaration.
Linc Board Meeting Date
Linc Ltd announced that its Board of Directors meeting is scheduled for 5 November 2026. The agenda includes approval of unaudited financial results for Q1 and H1 FY27.
NDR Auto Components Board Meeting Date
NDR Auto Components intimated its board meeting for November 4, 2026, to approve Q1 and H1 FY27 results. No financial figures are reported.
Reliance Chemotex Industries Board Meeting Date
Reliance Chemotex notified a Board Meeting on 05 Nov 2026 to approve unaudited results for Q1 FY27. No financial figures or decisions are yet reported.